Bispecifics In Oncology Market Statistics Expected To Experience Significant Growth By 2040, According To Delveinsight

(MENAFN- GetNews) Bispecifics in Oncology Market Statistics Expected to Experience Significant Growth by 2040, According to DelveInsight

(Albany, US), September 16, 2026, DelveInsight's“Bispecifics in Oncology Market Insights, Epidemiology, and Market Forecast-2040′′ report provides a detailed understanding of the Bispecifics in Oncology, including historical and projected epidemiology, as well as market trends in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

This latest healthcare forecast report delivers a comprehensive analysis of Bispecifics in Oncology, offering insights into revenue trends, prevalence, and the treatment landscape. The report highlights key Bispecifics in Oncology statistics, examining current and projected market sizes, as well as the development and efficacy of emerging therapies. Additionally, it provides an overview of ongoing and upcoming clinical trials that are expected to shape the future of Bispecifics in Oncology treatment. This report serves as an essential resource for understanding market dynamics and the evolving therapeutic landscape of Bispecifics in Oncology.

To Know in detail about the Bispecifics in Oncology market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bispecifics in Oncology Market Forecast

Key Highlights of the Bispecifics in Oncology Market Report:

• The Bispecifics in Oncology market size is expected to grow at a robust CAGR during the study period (2020-2040).

• Leading Bispecifics in Oncology Companies: AstraZeneca, I-MAB Biopharma and BMS, BioNTech, Bristol Myers Squibb, and others.

• Prominent Bispecifics in Oncology Therapies: Volrustomig, Givastomig, BNT327, and more.

• Growth in the market is driven by increasing disease prevalence and awareness, alongside the introduction of multiple-stage pipeline products.

• According to DelveInsight, approximately 74,900 new cases of multiple myeloma were reported across the 7MM in 2024, with numbers projected to rise during the forecast period.

• In 2024, Germany and France recorded the highest number of new multiple myeloma cases within the EU4 and the UK, collectively accounting for about 24% of total cases, whereas Spain reported the lowest.

• In the United States, around 895,600 individuals were estimated to be eligible for bispecific antibody therapies in oncology.

• Non-small cell lung cancer (NSCLC) represents approximately 85% of all lung cancer cases, making it the predominant form.

• In 2024, the 7MM saw an estimated 211,550 new cases of gastric cancer, including gastroesophageal junction (GEJ) tumors, with projections indicating growth by 2040.

• Japan reported roughly 121,910 new cases of NSCLC in 2024.

Bispecifics in Oncology Overview Bispecifics in oncology refer to bispecific antibodies-engineered therapeutic proteins designed to simultaneously bind two different targets. Unlike conventional monoclonal antibodies, which attach to a single antigen, bispecific antibodies engage both a tumor-associated antigen and an immune cell receptor, such as CD3 on T cells. This dual engagement enhances the immune system's ability to recognize and destroy cancer cells. Bispecifics are emerging as a powerful modality in cancer immunotherapy, with several approved therapies for leukemia and lymphoma and numerous candidates in clinical development for solid tumors.

Get a Free sample for the Bispecifics in Oncology Market Forecast, Size & Share Analysis Report: delveinsight/report-store/bispecifics-in-oncology-market-forecast

Recent Developments in the Bispecifics in Oncology Treatment Landscape:

• In July 2025, I-Mab presented promising Phase Ib combination results for givastomig, administered with nivolumab and mFOLFOX6 for gastric cancer, at the 2025 European Society for Medical Oncology Gastrointestinal Cancers Congress.

• In June 2025, BioNTech and Bristol Myers Squibb announced a global partnership to co-develop and co-commercialize BioNTech's investigational bispecific antibody BNT327 for multiple solid tumor types, aiming to accelerate development and global access.

Bispecifics in Oncology Epidemiology The epidemiology section details historical, current, and projected trends in the 7MM from 2020 to 2040. It helps understand the drivers behind these trends by reviewing numerous studies and key opinion leader perspectives. The section also analyzes diagnosed patient populations and future projections.

Bispecifics in Oncology Epidemiology Segmentation: The Bispecifics in Oncology market report provides epidemiological insights from 2020–2040 in the 7MM, segmented into:

• Total Prevalence of Bispecifics in Oncology

• Prevalent Cases by Severity

• Gender-specific Prevalence

• Diagnosed Cases of Episodic and Chronic Bispecifics in Oncology

Download the report to explore the factors driving Bispecifics in Oncology epidemiology trends @ Bispecifics in Oncology Epidemiology Forecast

Bispecifics in Oncology Drugs Uptake and Pipeline Development Activities The drug uptake section examines the adoption rate of recently launched or soon-to-be-launched drugs in the Bispecifics in Oncology market. It covers market uptake by drugs, patient adoption by therapy, and sales of individual drugs.

The therapeutic assessment section identifies the fastest-adopted drugs and the reasons for their high utilization, comparing drugs by market share. The report also provides insights into pipeline development, covering therapeutic candidates at various stages, key companies involved, and recent developments like collaborations, acquisitions, mergers, and licensing.

Bispecifics in Oncology Therapies and Key Companies:

• Volrustomig: AstraZeneca

• Givastomig: I-MAB Biopharma and BMS

• BNT327: BioNTech and Bristol Myers Squibb

Discover more about therapies set to capture significant Bispecifics in Oncology market share @ Bispecifics in Oncology Treatment Landscape

Bispecifics in Oncology Market Drivers:

• Rising prevalence of cancers, including hematologic and solid tumors, fueling demand for innovative therapies

• Increasing adoption of immunotherapy and targeted treatments, positioning bispecific antibodies as a promising approach

• Advances in biotechnology and antibody engineering enabling development of safer, more effective bispecifics

• Growing investments and collaborations among pharma companies accelerating R&D and commercialization

Bispecifics in Oncology Market Barriers:

• High development and manufacturing costs for complex bispecific antibody production

• Potential safety concerns, such as cytokine release syndrome and off-target effects

• Challenges in optimizing dosing, stability, and delivery for different cancer types

• Stringent regulatory requirements and lengthy approval timelines for novel oncology biologics

Scope of the Bispecifics in Oncology Market Report:

• Study Period: 2020–2040

• Coverage: 7MM [United States, EU5 (Germany, France, Italy, Spain, UK), Japan]

• Key Companies: AstraZeneca, I-MAB Biopharma and BMS, BioNTech, Bristol Myers Squibb, others

• Key Therapies: Volrustomig, Givastomig, BNT327, and others

• Therapeutic Assessment: Current marketed and emerging therapies

• Market Dynamics: Drivers and barriers

• Competitive Intelligence: SWOT, PESTLE, Porter's Five Forces, BCG Matrix, market entry strategies

• Unmet Needs, KOL and Analyst insights, Market Access, and Reimbursement

To learn more about companies working on Bispecifics in Oncology, visit @ Bispecifics in Oncology Clinical Trials and Therapeutic Assessment

Table of Contents:

Bispecifics in Oncology Market Report Introduction

Executive Summary

SWOT Analysis

Patient Share Overview

Market Overview

Disease Background

Epidemiology and Patient Population

Country-Specific Population

Current Treatment and Medical Practices

Unmet Needs

Emerging Therapies

Market Outlook

Country-Wise Market Analysis (2020–2040)

Market Access and Reimbursement

Market Drivers

Market Barriers

Appendix

Report Methodology

DelveInsight Capabilities

Disclaimer

About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

MENAFN17092026003238003268ID1111677185